Home

ThioLogics is developing a groundbreaking technology platform that will enable the homogeneous modification of native proteins.

We are particularly focused on the application of our technology to the assembly of homogeneous antibody conjugates.

Technology that will allow modification of antibodies to yield well-defined, homogeneous products is highly desirable. In particular, it has been demonstrated that homogeneous antibody drug conjugates (ADCs) have a greatly improved therapeutic index over analogous heterogeneous formulations. Introducing greater homogeneity into antibody conjugates will also greatly simplify process and development issues, reducing costs.